Targeted Agents for Adjuvant Therapy of Colon Cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 11, 2006, Pages 42-45

  de Gramont, Aimery ^a   Tournigand, Christophe ^a   André, Thierry ^a   Larsen, Annette K ^a   Louvet, Christophe ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADD ON THERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 18Q; CLINICAL TRIAL; COLON CANCER; DISEASE FREE SURVIVAL; DRUG SAFETY; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL RATE; TOXICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; HUMANS;

EID: 33845394635     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2006.10.006     Document Type: Article

References (15)

1. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
2. Tabernero J., Van Cutsem E., Sastre J., et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 23 (2004) 1092s (abstr 3512)
3. Moertel C.G., Fleming T.R., Macdonald J.S., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322 (1990) 399-401
4. IMPACT investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345 (1995) 939-944
5. Haller D.G., Catalano P.J., Macdonald J.S., et al. Phase III study of fluorouracil, Leucovorin, and Levamisole in high-risk stage II and III colon cancer/ final report of Intergroup 0089. J Clin Oncol 23 (2005) 8671-8678
6. Wolmark N., Rockette H., Mamounas E., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole, in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-04. J Clin Oncol 17 (1999) 3553-3559
7. O'Connell M.J., Mailliard J.A., Kahn M.J., et al. Controlled trial of fluorouracil and low-dose leucovorin given 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15 (1997) 246-250
8. André T., Colin P., Louvet C., et al. Semimonthly vs. monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: Results of a randomized trial. J Clin Oncol 21 (2003) 2896-2903
9. Twelves C., Wong A., Nowacki M.P., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
10. Saltz L.B., Niedzwiecki D., Hollis D., et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (Intergroup trial CALGB C89803). Proc Am Soc Clin Oncol 23 (2004) 246 (abstr 3500)
11. Ychou M., Raoul J., Douillard J., et al. A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802). J Clin Oncol 23; (2005) 246s (abstr 3502)
12. van Cutsem E., Labianca R., Hossfeld D., et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts) (PETACC 3). J Clin Oncol 23 (2005) 3s (abstr LBA8)
13. André T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, 5-fluorouracil and leucovorin as adjuvant treatment of colon cancer: results of the international randomized MOSAIC trial. N Engl J Med 350 (2004) 2343-2351
14. de Gramont A., Boni C., Navarro J., et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. J Clin Oncol 23 (2005) 246s (abstr 3501)
15. Wolmark N., Wieand H.S., Kuebler J.P., et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. J Clin Oncol 23 (2005) 16s (abstr LBA3500)